Asia-Pacific Organ Preservation Market Size, Country Analysis and Forecast, 2026–2035

Asia-Pacific Organ Preservation Market Size & Forecast 2035

The Asia-Pacific organ preservation market was valued at USD 46.6 million in 2025 and is projected to reach USD 101.5 million by 2035, expanding at an 8.1% CAGR during 2026-2035. 

Static cold storage remains the clinical and revenue foundation because it is widely available, familiar to transplant teams and less capital intensive than machine perfusion. The market is nevertheless shifting toward hypothermic oxygenated and normothermic perfusion, particularly for donation after circulatory death, extended-criteria donors and organs that require functional assessment before acceptance. Growth will depend on transplant-center capacity, device approval, trained perfusion staff, reimbursement and the ability to coordinate retrieval across long distances.

Key Highlights

• 2025 market value: USD 46.6 million
• 2035 forecast: USD 101.5 million
• Forecast CAGR: 8.1% during 2026-2035
• Largest technique: Static cold storage, 60% or USD 28.0 million
• Largest solution: University of Wisconsin solution, 36% or USD 16.8 million
• Largest organ category: Kidney, 43% or USD 20.0 million
• Largest end user: Transplant hospitals and centers, 78% or USD 36.3 million
• Largest country market: China, 27% or USD 12.6 million
• Japan market: 22% or USD 10.3 million

Market Definition and Scope

Organ preservation begins when circulation to a donated organ ends and continues until reperfusion in the recipient. Static cold storage lowers temperature and metabolism using a preservation solution and insulated transport container. Hypothermic machine perfusion circulates a cold solution through the organ, with oxygenation added in selected systems. Normothermic machine perfusion supplies warm oxygenated perfusate, allowing physiological activity and functional assessment outside the donor.

The scope includes University of Wisconsin, Custodiol HTK, Perfadex and other preservation solutions; organ-specific cold-transport devices; machine-perfusion consoles; and related single-use sets. It excludes transplant surgery, immunosuppressive drugs, donor testing performed independently of preservation, general hospital refrigeration and cell or tissue biobanking.

Market Dynamics

Marginal-organ utilization is changing the preservation objective

Traditional preservation aims to slow injury during transport. Machine perfusion adds assessment, conditioning and, in some cases, therapeutic intervention. This is important when donor age, warm ischemia, steatosis or prolonged transport makes acceptance uncertain. A system that converts an otherwise declined organ into a transplantable graft creates value beyond storage time, but the clinical and economic case must be demonstrated by organ type.

Kidney volume supports scale, while thoracic organs support higher revenue per case

Kidneys account for the largest transplant volume and can tolerate longer cold storage than hearts or lungs. They support recurring demand for cold-storage solution and hypothermic perfusion disposables. Heart and lung cases are lower volume but require tighter time control, specialized transport and higher-value technologies. This creates a two-tier market: volume-led abdominal preservation and technology-led thoracic preservation.

Donation after circulatory death increases demand for active preservation

DCD organs experience warm ischemia before procurement. Perfusion systems can restore controlled circulation, provide oxygen and generate viability information. Adoption requires protocol development across donor hospitals, retrieval teams and recipient centers. The system must fit the entire pathway; purchasing a console without trained operators and transport coordination will not deliver higher utilization.

Geography makes transport infrastructure a clinical variable

Asia-Pacific includes densely connected urban transplant networks and remote donor locations separated by long air routes. Australia, Japan, Indonesia, the Philippines and Pacific markets face island or continental-distance constraints. China and India manage large territories with uneven transplant-center capability. Temperature records, flight access, handoffs and equipment portability therefore affect preservation performance alongside the solution or device itself.

Reimbursement and capital budgets separate mature and emerging markets

Static cold storage has a low entry cost and can be used across hospitals. Machine perfusion requires capital equipment, consumables, maintenance, clinical support and specialist staffing. Japan, Australia, South Korea and selected Chinese centers are positioned to adopt advanced systems earlier. India and Southeast Asia can expand through high-volume referral centers, shared equipment and organ-specific protocols rather than broad deployment at every hospital.

Regulatory approval is product- and country-specific

Approval in the United States or Europe does not automatically permit sale in Asia-Pacific. Sponsors must establish local device registration, sponsor arrangements, labeling and post-market support. Australia's Therapeutic Goods Administration listed an XVIVO-manufactured Class IIa organ-preservation solution in April 2026. Availability of a solution, console and disposable set may involve separate registrations, making portfolio sequencing important.

Evidence standards are rising

Transplant teams evaluate graft survival, primary non-function, delayed graft function, intensive-care use and discard rates. Preservation time alone is an incomplete endpoint. Controlled studies, real-world registries and transparent device-status statements will determine adoption. Investigational products must not be presented as approved simply because clinical results have been published.

Market Segmentation

By Preservation Technique

Static cold storage held 60% of 2025 revenue, equal to USD 28.0 million. It remains the standard method across most kidney, liver, heart and lung procurement pathways because it is portable, inexpensive and embedded in clinical practice. Revenue includes preservation fluid and organ-transport products. Its share is expected to decline even as absolute sales rise.

Hypothermic machine perfusion represented 24%, or USD 11.2 million. Kidney perfusion forms the installed base, while oxygenated approaches for liver and heart preservation are expanding. The segment benefits from lower-temperature metabolic protection combined with continuous circulation and selected viability indicators.

Normothermic machine perfusion accounted for 13%, equal to USD 6.1 million. Liver, heart and lung systems support functional assessment under near-physiological conditions. High equipment, disposable and staffing costs limit adoption to well-resourced centers.

Other techniques, including controlled oxygenated rewarming and experimental subnormothermic approaches, held 3%, or USD 1.4 million. These remain concentrated in research and early clinical programs.

By Preservation Solution

University of Wisconsin solution held 36% of 2025 revenue, equal to USD 16.8 million. It remains widely used for abdominal-organ preservation and provides an established benchmark for kidney, liver and pancreas protocols.

Custodiol HTK represented 23%, or USD 10.7 million. Its low-viscosity formulation supports flushing and preservation across selected abdominal and thoracic applications. Institutional protocol, surgeon preference and procurement contracts influence use.

Perfadex and related lung-preservation solutions accounted for 18%, equal to USD 8.4 million. Growth is supported by lung-transplant programs and ex-vivo lung-perfusion pathways. The category is forecast to gain share as thoracic programs expand.

Citrate, Collins, machine-specific perfusates and other solutions formed 23%, or USD 10.7 million. The segment includes kidney perfusion fluids, proprietary system consumables and organ-specific formulations.

By Organ Type

Kidneys held 43% of 2025 revenue, equal to USD 20.0 million. High procedure volume, deceased-donor transport and machine-perfusion use support leadership. Preservation quality also affects delayed graft function and hospital-resource use.

Livers represented 24%, or USD 11.2 million. Steatotic and DCD grafts create demand for oxygenated hypothermic and normothermic assessment. Terumo's OrganOx platform places a major Japanese medtech company directly in this segment.

Lungs accounted for 15%, equal to USD 7.0 million. Perfadex-based storage and ex-vivo lung perfusion support utilization of donor lungs that require additional evaluation.

Hearts held 12%, or USD 5.6 million. Short conventional preservation windows and sensitivity to ischemia create strong value per case for controlled cold transport, hypothermic oxygenated perfusion and normothermic systems.

Pancreas, intestine and multivisceral grafts formed 6%, equal to USD 2.8 million. Low procedure numbers restrict revenue, although these grafts require precise preservation protocols.

By Product Category

Preservation solutions and perfusates generated 45% of 2025 revenue, or USD 21.0 million. Machine-perfusion consoles represented 27%, or USD 12.6 million. Single-use circuits, cannulae and organ chambers held 18%, or USD 8.4 million, while insulated transport and temperature-monitoring systems accounted for 10%, or USD 4.7 million. Consumables create recurring revenue after platform installation, making console placement an important indicator of future sales.

By End User

Transplant hospitals and specialist centers held 78% of 2025 revenue, equal to USD 36.3 million. Organ-procurement organizations, donor coordination networks and tissue establishments represented 14%, or USD 6.5 million. Universities and research institutes accounted for 8%, or USD 3.7 million, including translational work on perfusion protocols, biomarkers and organ repair.

Country-Level Analysis

China

China held 27% of the regional market, equal to USD 12.6 million in 2025. The country combines high end-stage organ-disease burden with expanding transplant-center capability. Advanced adoption is concentrated in large academic hospitals. Local device development and domestic preservation-solution manufacturing can reduce procurement costs, but clinical standardization, traceability and transparent allocation remain essential to broader international confidence.

Japan

Japan represented 22%, or USD 10.3 million. The country has sophisticated tertiary hospitals and strong medtech capabilities, but deceased-donor supply limits procedure volume. The strategic market is therefore centred on improving utilization of each available organ. Terumo completed its acquisition of OrganOx in October 2025 and established Terumo Organ Technologies, placing a Japan-headquartered company in normothermic liver perfusion. In October 2026, Terumo and the University of Oxford began a six-year collaboration to advance organ-perfusion technologies and new applications.

Australia and New Zealand

Australia and New Zealand held 15%, equal to USD 7.0 million. Long retrieval distances make reliable transport, temperature control and portable perfusion important. Australia also provides a clear regulatory route through the TGA. Specialist transplant centers support adoption, while the smaller population limits the number of platforms that can be economically deployed.

India

India accounted for 14%, or USD 6.5 million. Living-donor kidney and liver transplantation forms a major part of activity, while deceased-donor programs differ by state. Expansion depends on coordination between donor hospitals, green corridors, air transport and recipient centers. Capital-intensive perfusion will initially remain concentrated in high-volume private and academic institutions.

South Korea

South Korea represented 9%, equal to USD 4.2 million. Dense urban infrastructure, advanced hospitals and high clinical-technology adoption support preservation-system demand. Kidney and liver programs form the core, with thoracic perfusion representing a smaller high-value opportunity.

Southeast Asia and the Rest of Asia-Pacific

Southeast Asia and the remaining regional markets held 13%, or USD 6.1 million. Singapore provides a specialist hub, while Thailand, Malaysia, Indonesia, the Philippines and Vietnam have uneven transplant capacity. WHO's regional work identifies regulation, infrastructure, technical expertise, political commitment and cost as core requirements. Growth will be concentrated in national referral centers rather than evenly distributed.

Country and segment values are analytical 2025 revenue allocations reconciled to the USD 46.6 million regional total. They measure commercial preservation products and systems, not transplant procedure value.

Competitive Landscape

The market includes preservation-solution suppliers, cold-transport specialists and machine-perfusion platform companies. Relevant participants include XVIVO Perfusion, TransMedics, Terumo Organ Technologies/OrganOx, Getinge/Paragonix, Bridge to Life, Organ Recovery Systems, Global Transplant Solutions and regional distributors. Competition is moving toward complete pathways that combine a console, disposables, clinical support, data and logistics.

XVIVO Perfusion

XVIVO develops preservation solutions and perfusion systems for lungs, hearts, kidneys and livers. Relevant products include Perfadex Plus, STEEN Solution, XPS, Kidney Assist and the Heart Assist Transport system. The company reported SEK 732.5 million in sales for January-September 2026, up 25% in reported currency, with thoracic sales increasing 43% in local currencies. Its regulatory work in heart preservation and installed lung expertise make it a key supplier for advanced transplant centers. Market availability differs by country and device.

TransMedics

TransMedics developed the Organ Care System for heart, lung and liver preservation in a warm, functioning state. The company combines equipment, single-use sets and clinical-logistics support. Its development pipeline includes next-generation OCS systems and a potential kidney platform. Asia-Pacific expansion requires local approvals, trained clinical teams and logistics coverage; the U.S. National OCS Program model cannot be transferred without adapting transport operations to each country's geography and regulation.

Terumo Organ Technologies and OrganOx

Terumo acquired OrganOx to enter the organ-transplantation technology sector. OrganOx metra provides normothermic liver perfusion and supports preservation, assessment and transport. The combination connects Oxford-developed perfusion technology with Terumo's manufacturing, regulatory and commercial infrastructure in Japan and other Asia-Pacific markets. The October 2026 six-year Oxford partnership is intended to advance perfusion platforms and explore transplant and patient-connected applications.

Getinge and Paragonix Technologies

Getinge acquired Paragonix in 2024. Paragonix offers organ-specific controlled hypothermic transport systems spanning heart, lung, kidney, liver and pancreas applications, together with digital monitoring and transplant-support services. The portfolio addresses an intermediate position between ice-based storage and full machine perfusion by controlling temperature and protecting organs from physical contact with ice. Getinge's hospital relationships can support international distribution, subject to local registrations.

Recent Developments

• October 22, 2026 - XVIVO: Reported January-September sales of SEK 732.5 million, 25% higher in reported currency, with thoracic sales up 43% in local currencies.
• October 14, 2026 - Terumo and the University of Oxford: Began a six-year research collaboration to advance organ-perfusion technologies and investigate new transplant and patient-connected applications.
• September 28, 2026 - XVIVO: Announced FDA receipt of its PMA application for the Heart Assist Transport system, supported by the 141-patient PRESERVE IDE trial and other evidence. The system remained investigational in the United States at that date.
• August 21, 2026 - OrganOx/Terumo: Welcomed NICE guidance supporting routine NHS funding and access to ex-situ machine perfusion for liver transplantation, strengthening the reimbursement evidence relevant to other health systems.
• August 11, 2026 - XVIVO: Received European CE certificates for the Heart Assist Transport system, enabling commercial availability in Europe while U.S. use remained investigational.
• July 6, 2026 - TransMedics: Completed its strategic investment in PAD Aviation to support a dedicated European transplant-logistics network, reinforcing the integration of preservation technology with transport.
• May 14, 2026 - OrganOx/Terumo: Appointed Naoya Iwata as CEO and President, effective June 1, to lead the organ-technology business following Terumo's acquisition.

Strategic Takeaways

• The market is moving from storage toward organ assessment. Perfusion platforms can provide physiological data that supports acceptance decisions for higher-risk grafts.
• Kidneys provide recurring volume, while liver, lung and heart systems deliver higher revenue per case. Portfolio strategy should separate these economic models.
• Japan's opportunity is organ utilization rather than high transplant volume. Technology that protects scarce donor organs has stronger relevance than broad capital deployment.
• Transport is part of the preservation product. Temperature control, trained teams, aviation access and handoff protocols directly affect clinical value.
• Console placements create a consumables annuity. Installed platforms drive repeat purchases of circuits, perfusates and organ-specific kits.
• Country registration can fragment regional launches. Solution, console and disposable approvals must be sequenced market by market.
• Reimbursement evidence from mature systems can influence Asia-Pacific procurement. Clinical benefit must be translated into avoided discard, complications and hospital days.

Asia-Pacific Organ Preservation Market Scope